Immunocore Holdings plc (NASDAQ: IMCR) has announced the upcoming departure of its Chief Financial Officer (CFO) and Head of Strategy, Brian Di Donato, who is set to leave at the end of the year to assume the role of Chief Executive Officer at a private, early-stage biotech company in San Diego, California. The company will commence a search for a new CFO, and Di Donato will continue in his current positions through the end of 2024 to ensure a smooth transition.
During Di Donato's tenure, Immunocore successfully raised significant capital to invest in its innovative platform and rapidly growing clinical and research portfolio. The company's most advanced oncology TCR therapeutic, Kimmtrak, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries.
Under Di Donato's leadership, Immunocore became a commercial-stage biotech company, with the launch of the world's first TCR therapy. The company has nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases, with planned data readouts for three phase 3 clinical trials and expansion into autoimmune diseases.
Bahija Jallal, Chief Executive Officer at Immunocore, praised Di Donato's leadership, stating that he built a successful finance department and leaves a proven team that will continue supporting the company moving forward. Di Donato expressed his pride in the company's accomplishments and his privilege in being part of its journey, looking forward to its continued success.
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called Immtax, designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf Immtax platform, the company is developing a deep pipeline in multiple therapeutic areas.
Immunocore's accomplishments under Di Donato's leadership demonstrate the company's commitment to advancing transformative immunomodulating medicines and its continued growth and success in the biotechnology sector. Following these announcements, the company's shares moved -4.3%, and are now trading at a price of $34.6. If you want to know more, read the company's complete 8-K report here.
